 Christina Jamieson
|
| Title(s) | Associate Professor In Residence, Urology |
|---|
| School | Health Sciences |
|---|
| Phone | 858-534-2921 |
|---|
| vCard | Download vCard |
|---|
|
|
 Overview Dr. Jamieson's research is focused on elucidating mechanisms of therapy resistance in bone metastatic urologic cancers using patient-derived xenograft (PDX) models and 3D in vitro models. She is applying her expertise in genome-wide analyses of prostate cancer tumors and primary patient-derived tumor models to translate next generation genomics on prostate cancers into practical applications and novel therapies that will improve and, she hopes, eventually transform patient care.
Research Overview
Dr. Jamieson's research is focused on elucidating mechanisms of therapy resistance in bone metastatic urologic cancers using patient-derived xenograft (PDX) models and 3D in vitro models. She is applying her expertise in genome-wide analyses of prostate cancer tumors and primary patient-derived tumor models to translate next generation genomics on prostate cancers into practical applications and novel therapies that will improve and, she hopes, eventually transform patient care.
Research Topics
- Cancer
- Cell Biology
- Endocrinology
- Genomics
- Immunology
- Molecular Biology
- Regeneration/Stem Cells
- Translational Research
Current Project Titles
- Novel patient-derived xenograft models of bone metastatic prostate cancer.
- Genomic profiling of castration-resistant prostate cancer in the bone-niche.
ORNG Applications Bibliographic
-
Crumbaker M, Chan EKF, Gong T, Corcoran N, Jaratlerdsiri W, Lyons RJ, Haynes AM, Kulidjian AA, Kalsbeek AMF, Petersen DC, Stricker PD, Jamieson CAM, Croucher PI, Hovens CM, Joshua AM, Hayes VM. The Impact of Whole Genome Data on Therapeutic Decision-Making in Metastatic Prostate Cancer: A Retrospective Analysis. Cancers (Basel). 2020 May 07; 12(5). PMID: 32392735.
-
Lee S, Burner DN, Mendoza TR, Muldong MT, Arreola C, Wu CN, Cacalano NA, Kulidjian AA, Kane CJ, Jamieson CAM. Establishment and Analysis of Three-Dimensional (3D) Organoids Derived from Patient Prostate Cancer Bone Metastasis Specimens and their Xenografts. J Vis Exp. 2020 Feb 03; (156). PMID: 32065165.
-
Toth RK, Tran JD, Muldong MT, Nollet EA, Schulz VV, Jensen CC, Hazlehurst LA, Corey E, Durden D, Jamieson C, Miranti CK, Warfel NA. Hypoxia-induced PIM kinase and laminin-activated integrin a6 mediate resistance to PI3K inhibitors in bone-metastatic CRPC. Am J Clin Exp Urol. 2019; 7(4):297-312. PMID: 31511835.
-
Venkadakrishnan VB, DePriest AD, Kumari S, Senapati D, Ben-Salem S, Su Y, Mudduluru G, Hu Q, Cortes E, Pop E, Mohler JL, Azabdaftari G, Attwood K, Shah RB, Jamieson C, Dehm SM, Magi-Galluzzi C, Klein E, Sharifi N, Liu S, Heemers HV. Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strategy. Oncogene. 2019 06; 38(23):4496-4511. PMID: 30742064.
-
Parsons JK, Pinto PA, Pavlovich CP, Uchio E, Kim HL, Nguyen MN, Gulley JL, Jamieson C, Hsu P, Wojtowicz M, Parnes H, Schlom J, Dahut WL, Madan RA, Donahue RN, Chow HS. A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study. Eur Urol Focus. 2018 09; 4(5):636-638. PMID: 30197041.
-
Lee GT, Kwon SJ, Kim J, Kwon YS, Lee N, Hong JH, Jamieson C, Kim WJ, Kim IY. WNT5A induces castration-resistant prostate cancer via CCL2 and tumour-infiltrating macrophages. Br J Cancer. 2018 03 06; 118(5):670-678. PMID: 29381686.
-
Hirata T, Park SC, Muldong MT, Wu CN, Yamaguchi T, Strasner A, Raheem O, Kumon H, Sah RL, Cacalano NA, Jamieson CHM, Kane CJ, Masuda K, Kulidjian AA, Jamieson CAM. Specific bone region localization of osteolytic versus osteoblastic lesions in a patient-derived xenograft model of bone metastatic prostate cancer. Asian J Urol. 2016 Oct; 3(4):229-239. PMID: 29264191.
-
Shalapour S, Font-Burgada J, Di Caro G, Zhong Z, Sanchez-Lopez E, Dhar D, Willimsky G, Ammirante M, Strasner A, Hansel DE, Jamieson C, Kane CJ, Klatte T, Birner P, Kenner L, Karin M. Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature. 2015 May 07; 521(7550):94-8. PMID: 25924065.
-
Godebu E, Muldong M, Strasner A, Wu CN, Park SC, Woo JR, Ma W, Liss MA, Hirata T, Raheem O, Cacalano NA, Kulidjian AA, Jamieson CA. PCSD1, a new patient-derived model of bone metastatic prostate cancer, is castrate-resistant in the bone-niche. J Transl Med. 2014 Oct 03; 12:275. PMID: 25278011.
-
Ammirante M, Shalapour S, Kang Y, Jamieson CA, Karin M. Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts. Proc Natl Acad Sci U S A. 2014 Oct 14; 111(41):14776-81. PMID: 25267627.
-
Woo JR, Liss MA, Muldong MT, Palazzi K, Strasner A, Ammirante M, Varki N, Shabaik A, Howell S, Kane CJ, Karin M, Jamieson CA. Tumor infiltrating B-cells are increased in prostate cancer tissue. J Transl Med. 2014 Jan 30; 12:30. PMID: 24475900.
-
Goff DJ, Court Recart A, Sadarangani A, Chun HJ, Barrett CL, Krajewska M, Leu H, Low-Marchelli J, Ma W, Shih AY, Wei J, Zhai D, Geron I, Pu M, Bao L, Chuang R, Balaian L, Gotlib J, Minden M, Martinelli G, Rusert J, Dao KH, Shazand K, Wentworth P, Smith KM, Jamieson CA, Morris SR, Messer K, Goldstein LS, Hudson TJ, Marra M, Frazer KA, Pellecchia M, Reed JC, Jamieson CH. A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell. 2013 Mar 07; 12(3):316-28. PMID: 23333150.
-
Ma W, Gutierrez A, Goff DJ, Geron I, Sadarangani A, Jamieson CA, Court AC, Shih AY, Jiang Q, Wu CC, Li K, Smith KM, Crews LA, Gibson NW, Deichaite I, Morris SR, Wei P, Carson DA, Look AT, Jamieson CH. NOTCH1 signaling promotes human T-cell acute lymphoblastic leukemia initiating cell regeneration in supportive niches. PLoS One. 2012; 7(6):e39725. PMID: 22768113.
-
Raheem O, Kulidjian AA, Wu C, Jeong YB, Yamaguchi T, Smith KM, Goff D, Leu H, Morris SR, Cacalano NA, Masuda K, Jamieson CH, Kane CJ, Jamieson CA. A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions. J Transl Med. 2011 Oct 28; 9:185. PMID: 22035283.
-
Belanto JJ, Diaz-Perez SV, Magyar CE, Maxwell MM, Yilmaz Y, Topp K, Boso G, Jamieson CH, Cacalano NA, Jamieson CA. Dexamethasone induces dysferlin in myoblasts and enhances their myogenic differentiation. Neuromuscul Disord. 2010 Feb; 20(2):111-21. PMID: 20080405.
-
Peng L, Wu TT, Tchieu JH, Feng J, Brown HJ, Feng J, Li X, Qi J, Deng H, Vivanco I, Mellinghoff IK, Jamieson C, Sun R. Inhibition of the phosphatidylinositol 3-kinase-Akt pathway enhances gamma-2 herpesvirus lytic replication and facilitates reactivation from latency. J Gen Virol. 2010 Feb; 91(Pt 2):463-9. PMID: 19864499.
-
Sitko JC, Yeh B, Kim M, Zhou H, Takaesu G, Yoshimura A, McBride WH, Jewett A, Jamieson CA, Cacalano NA. SOCS3 regulates p21 expression and cell cycle arrest in response to DNA damage. Cell Signal. 2008 Dec; 20(12):2221-30. PMID: 18793717.
-
Zhou H, Miki R, Eeva M, Fike FM, Seligson D, Yang L, Yoshimura A, Teitell MA, Jamieson CA, Cacalano NA. Reciprocal regulation of SOCS 1 and SOCS3 enhances resistance to ionizing radiation in glioblastoma multiforme. Clin Cancer Res. 2007 Apr 15; 13(8):2344-53. PMID: 17438093.
-
Poon MM, Choi SH, Jamieson CA, Geschwind DH, Martin KC. Identification of process-localized mRNAs from cultured rodent hippocampal neurons. J Neurosci. 2006 Dec 20; 26(51):13390-9. PMID: 17182790.
-
Jamieson CA, Yamamoto KR. Crosstalk pathway for inhibition of glucocorticoid-induced apoptosis by T cell receptor signaling. Proc Natl Acad Sci U S A. 2000 Jun 20; 97(13):7319-24. PMID: 10860997.
|
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
|